Surgical Science Sweden AB
WKN: A2P46G / ISIN: SE0014428512Surgical Science Sweden (WKN: A2P46G)
| eröffnet am: | 11.02.21 10:57 von: | Tamakoschy |
| neuester Beitrag: | 30.11.23 09:29 von: | tinelli |
| Anzahl Beiträge: | 13 | |
| Leser gesamt: | 10848 | |
| davon Heute: | 9 | |
bewertet mit 0 Sternen |
||
|
|
||
11.02.21 10:57
#1
Tamakoschy
Surgical Science Sweden (WKN: A2P46G)
Surgical Science Sweden AB ist ein in Schweden ansässiges Unternehmen, das Virtual-Reality-Simulatoren für evidenzbasiertes laparoskopisches und endoskopisches Training anbietet. Die Systeme umfassen LapSim-, EndoSim- und TeamSim-Schulungen. Jedes Training kombiniert Grafiken und kognitive Instruktionen, beinhaltet die Navigation auf Touchscreens und verfügt über taktile Feedback-Technologie. Die LapSim-Schulungen bestehen aus laparoskopischen Übungen, die von grundlegender Navigation bis zu fortgeschrittenem Nähen reichen, die endoskopischen Übungen von EndoSim reichen von Funktionen des Zielfernrohrgriffs und des Tubus bis zur Schleifenreduktion. TeamSim umfasst Prozedurmodule für das Training in einer realen Operationssaalumgebung und hilft, die Kommunikationsfähigkeiten des Teams in Krisen- und Routinesituationen aufzubauen. Die Trainingssysteme werden von medizinischen Ausbildungszentren und Instituten weltweit für die Praxis, Validierung und Zertifizierung von Studenten, Chirurgen und Ärzten eingesetzt.
Heute wieder mit guten Zahlen. Ich bin ab heute mit einer Anfangsposiition investiert. Leider in D nur schwer handelbar. Deshalb sollte man möglichst in Stockholm kaufen.
https://www.marketscreener.com/quote/stock/...D-OF-THE-YEAR-32414586/
2/11/2021 | 07:31am GMT
FOURTH QUARTER 2020 (OCT - DEC)
Net sales amounted to SEK 39.6 million (39.3), corresponding to an increase of 1 percent compared with the corresponding period in the preceding year.
Operating profit amounted to SEK 12.6 million (12.4).
Net profit amounted to SEK 10.6 million (9.2), corresponding to earnings per share of SEK 0.31 (0.27).
Cash flow from operating activities amounted to SEK 16.7 million (7.9). As of December 31, 2020, cash and cash equivalents amounted to SEK 87.2 million (69.2).
FULL-YEAR 2020
Net sales amounted to SEK 104.8 million (101.5), corresponding to an increase of 3 percent compared with the corresponding period in the preceding year.
For comparable units, sales decreased by 19 percent.
Operating profit amounted to SEK 20.0 million (15.2).
Net profit amounted to SEK 15.6 million (12.6), corresponding to earnings per share of SEK 0.45 (0.45).
Cash flow from operating activities amounted to SEK 23.2 million (55.2).
FOLLOWING THE CLOSE OF THE YEAR
On January 20, 2021, a conditional agreement was entered into to acquire all of the shares in Mimic Technologies Inc. ("Mimic"), which operates in the area of robotic surgery. Mimic is based in Seattle in the US, and the acquisition provides Surgical Science with an additional customer base in robotic surgery, contributes data collection/analysis technology and significantly strengthens the presence in the important US market. The initial purchase consideration was USD 18 million (approximately SEK 150 million) on a cash and debt-free basis. In addition, a maximum USD 15.6 million (approximately SEK 130 million) may be paid as a deferred contingent consideration.
A private placement of approximately SEK 322 million was implemented, in which a number of new and existing Swedish and international institutional investors subscribed for shares. The transfer of ownership took place on January 27, 2021, once all of the terms of transfer had been met. Mimic will be consolidated within Surgical Science as of the transfer date.
Gothenburg, Sweden, February 11, 2021
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
For further information, please contact:
Gisli Hennermark, CEO
Telephone: +46 70 420 83 00
E-mail: gisli.hennermark@surgicalscience.com
Anna Ahlberg, CFO
Telephone: +46 70 855 38 35
E-mail: anna.ahlberg@surgicalscience.com
Heute wieder mit guten Zahlen. Ich bin ab heute mit einer Anfangsposiition investiert. Leider in D nur schwer handelbar. Deshalb sollte man möglichst in Stockholm kaufen.
https://www.marketscreener.com/quote/stock/...D-OF-THE-YEAR-32414586/
2/11/2021 | 07:31am GMT
FOURTH QUARTER 2020 (OCT - DEC)
Net sales amounted to SEK 39.6 million (39.3), corresponding to an increase of 1 percent compared with the corresponding period in the preceding year.
Operating profit amounted to SEK 12.6 million (12.4).
Net profit amounted to SEK 10.6 million (9.2), corresponding to earnings per share of SEK 0.31 (0.27).
Cash flow from operating activities amounted to SEK 16.7 million (7.9). As of December 31, 2020, cash and cash equivalents amounted to SEK 87.2 million (69.2).
FULL-YEAR 2020
Net sales amounted to SEK 104.8 million (101.5), corresponding to an increase of 3 percent compared with the corresponding period in the preceding year.
For comparable units, sales decreased by 19 percent.
Operating profit amounted to SEK 20.0 million (15.2).
Net profit amounted to SEK 15.6 million (12.6), corresponding to earnings per share of SEK 0.45 (0.45).
Cash flow from operating activities amounted to SEK 23.2 million (55.2).
FOLLOWING THE CLOSE OF THE YEAR
On January 20, 2021, a conditional agreement was entered into to acquire all of the shares in Mimic Technologies Inc. ("Mimic"), which operates in the area of robotic surgery. Mimic is based in Seattle in the US, and the acquisition provides Surgical Science with an additional customer base in robotic surgery, contributes data collection/analysis technology and significantly strengthens the presence in the important US market. The initial purchase consideration was USD 18 million (approximately SEK 150 million) on a cash and debt-free basis. In addition, a maximum USD 15.6 million (approximately SEK 130 million) may be paid as a deferred contingent consideration.
A private placement of approximately SEK 322 million was implemented, in which a number of new and existing Swedish and international institutional investors subscribed for shares. The transfer of ownership took place on January 27, 2021, once all of the terms of transfer had been met. Mimic will be consolidated within Surgical Science as of the transfer date.
Gothenburg, Sweden, February 11, 2021
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
For further information, please contact:
Gisli Hennermark, CEO
Telephone: +46 70 420 83 00
E-mail: gisli.hennermark@surgicalscience.com
Anna Ahlberg, CFO
Telephone: +46 70 855 38 35
E-mail: anna.ahlberg@surgicalscience.com
11.05.21 11:07
#2
Tamakoschy
Gute Zahlen - Kurs steigt gegen den Markttrend
https://view.news.eu.nasdaq.com/...566ebb192b98f3eb69ae7c&lang=en
nterim report January-March 2021: ACQUISITION OF MIMIC TECHNOLOGIES, STRONG GROWTH
FIRST QUARTER OF 2021 (JAN – MAR)
Net sales amounted to SEK 37.2 million (19.7), corresponding to an increase of 89 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 53 percent.
Operating profit amounted to SEK 2.2 million (loss 0.8). The outcome includes acquisition costs of SEK 6.0 million.
Net profit amounted to SEK 1.5 million (loss 0.7), corresponding to earnings per share of SEK 0.04 (loss 0.02).
Cash flow from operating activities was negative in the amount of SEK 8.9 million (5.3). As of March 31, 2021, cash and cash equivalents amounted to SEK 263.7 million (68.6).
On January 20, a conditional agreement was entered into to acquire all of the shares in Mimic Technologies Inc., which operates in the area of robotic surgery. Mimic is based in Seattle in the US, and the acquisition provides Surgical Science with an additional customer base in robotic surgery, contributes data collection/analysis technology and significantly strengthens the presence in the important US market. The initial valuation was USD 18 million (approximately SEK 150 million) on a cash and debt-free basis. In addition, a maximum USD 15.6 million (approximately SEK 130 million) may be paid as a deferred contingent consideration.
A directed share issue of approximately SEK 322 million was implemented, in which a number of new and existing Swedish and international institutional investors subscribed for shares. The transfer of ownership took place on January 27, once all of the terms of transfer had been met. Mimic was consolidated within Surgical Science as of the transfer date.
Gothenburg, Sweden, May 11, 2021
Surgical Science Sweden AB (publ)
nterim report January-March 2021: ACQUISITION OF MIMIC TECHNOLOGIES, STRONG GROWTH
FIRST QUARTER OF 2021 (JAN – MAR)
Net sales amounted to SEK 37.2 million (19.7), corresponding to an increase of 89 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 53 percent.
Operating profit amounted to SEK 2.2 million (loss 0.8). The outcome includes acquisition costs of SEK 6.0 million.
Net profit amounted to SEK 1.5 million (loss 0.7), corresponding to earnings per share of SEK 0.04 (loss 0.02).
Cash flow from operating activities was negative in the amount of SEK 8.9 million (5.3). As of March 31, 2021, cash and cash equivalents amounted to SEK 263.7 million (68.6).
On January 20, a conditional agreement was entered into to acquire all of the shares in Mimic Technologies Inc., which operates in the area of robotic surgery. Mimic is based in Seattle in the US, and the acquisition provides Surgical Science with an additional customer base in robotic surgery, contributes data collection/analysis technology and significantly strengthens the presence in the important US market. The initial valuation was USD 18 million (approximately SEK 150 million) on a cash and debt-free basis. In addition, a maximum USD 15.6 million (approximately SEK 130 million) may be paid as a deferred contingent consideration.
A directed share issue of approximately SEK 322 million was implemented, in which a number of new and existing Swedish and international institutional investors subscribed for shares. The transfer of ownership took place on January 27, once all of the terms of transfer had been met. Mimic was consolidated within Surgical Science as of the transfer date.
Gothenburg, Sweden, May 11, 2021
Surgical Science Sweden AB (publ)
13.07.21 20:13
#3
emiliopeloso
tolle aktie
bin investiert, das unternehmen ist profitabel und ohne schulden und wächst, nur die Aktie ist schon etwas teuer gegenüber dem Umsatz, alles gemäss marketscreener, die Aktie steigt seit einiger Zeit stetig
23.08.21 09:38
#4
Tamakoschy
Q2
https://www.marketscreener.com/quote/stock/...OSE-OF-PERIOD-36207586/
Interim report January-June 2021: CONTINUED STRONG GROWTH, KEY ACQUISITION FOLLOWING CLOSE OF PERIOD
08/20/2021 | 07:31am BST
SECOND QUARTER OF 2021 (APR – JUN)
Net sales amounted to SEK 36.6 million (20.6), corresponding to an increase of 77 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 45 percent.
Operating profit amounted to SEK 2.2 million (0.8).
Net profit amounted to SEK 3.5 million (loss 0.2), corresponding to earnings per share of SEK 0.09 (loss 0.01).
Cash flow from operating activities amounted to SEK 9.4 million (2.6). As of June 30, 2021, cash and cash equivalents amounted to SEK 267.3 million (68.4).
FIRST HALF OF 2021 (JAN – JUN)
Net sales amounted to SEK 73.8 million (40.3), corresponding to an increase of 83 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 49 percent.
Operating profit amounted to SEK 4.5 million (0.0). The outcome includes acquisition costs of SEK 6.0 million.
Net profit amounted to SEK 5.0 million (loss 0.9), corresponding to earnings per share of SEK 0.13 (loss 0.03).
Cash flow from operating activities amounted to SEK 0.5 million (outflow 2.6).
In January, Mimic Technologies Inc., was acquired, with operations in robotic surgery. Mimic is based in Seattle in the US, and the acquisition provides Surgical Science with an additional customer base in robotic surgery, contributes data collection/analysis technology and significantly strengthens the presence in the important US market. The transfer of ownership took place on January 27.
FOLLOWING THE CLOSE OF THE PERIOD
On July 28, it was announced that Surgical Science had entered into an agreement to acquire Simbionix. On August 16, an Extraordinary General Meeting was held, at which the directed share issue to finance the acquisition was approved. The transfer of ownership is expected within short.
Gothenburg, Sweden, August 20, 2021
Surgical Science Sweden AB (publ)
Interim report January-June 2021: CONTINUED STRONG GROWTH, KEY ACQUISITION FOLLOWING CLOSE OF PERIOD
08/20/2021 | 07:31am BST
SECOND QUARTER OF 2021 (APR – JUN)
Net sales amounted to SEK 36.6 million (20.6), corresponding to an increase of 77 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 45 percent.
Operating profit amounted to SEK 2.2 million (0.8).
Net profit amounted to SEK 3.5 million (loss 0.2), corresponding to earnings per share of SEK 0.09 (loss 0.01).
Cash flow from operating activities amounted to SEK 9.4 million (2.6). As of June 30, 2021, cash and cash equivalents amounted to SEK 267.3 million (68.4).
FIRST HALF OF 2021 (JAN – JUN)
Net sales amounted to SEK 73.8 million (40.3), corresponding to an increase of 83 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 49 percent.
Operating profit amounted to SEK 4.5 million (0.0). The outcome includes acquisition costs of SEK 6.0 million.
Net profit amounted to SEK 5.0 million (loss 0.9), corresponding to earnings per share of SEK 0.13 (loss 0.03).
Cash flow from operating activities amounted to SEK 0.5 million (outflow 2.6).
In January, Mimic Technologies Inc., was acquired, with operations in robotic surgery. Mimic is based in Seattle in the US, and the acquisition provides Surgical Science with an additional customer base in robotic surgery, contributes data collection/analysis technology and significantly strengthens the presence in the important US market. The transfer of ownership took place on January 27.
FOLLOWING THE CLOSE OF THE PERIOD
On July 28, it was announced that Surgical Science had entered into an agreement to acquire Simbionix. On August 16, an Extraordinary General Meeting was held, at which the directed share issue to finance the acquisition was approved. The transfer of ownership is expected within short.
Gothenburg, Sweden, August 20, 2021
Surgical Science Sweden AB (publ)
11.11.21 06:39
#5
irgendwie
Q3-Zahlen wieder beeindruckend
https://www.marketscreener.com/quote/stock/...ITH-SIMBIONIX-36965084/
Bin seit Juli 2020 investiert mit EK von 7,40€
DRITTES QUARTAL 2021 (JUL - SEP)
Der Nettoumsatz belief sich auf 95,3 Mio. SEK (24,9), was einer Steigerung von 282 Prozent gegenüber dem entsprechenden Vorjahreszeitraum entspricht. Simbionix ist in Höhe von 50,3 MSEK enthalten.
Bei vergleichbaren Einheiten stieg der Umsatz um 31 Prozent.
Das Betriebsergebnis belief sich auf 7,6 MSEK (7,3). Das Ergebnis enthält Erwerbskosten in Höhe von 21,8 MSEK.
Das Nettoergebnis belief sich auf 14,4 MSEK (5,9), was einem Ergebnis je Aktie von 0,33 MSEK (0,17) entspricht.
Der Cashflow aus betrieblicher Tätigkeit belief sich auf 51,6 MSEK (9,2). Zum 30. September 2021 beliefen sich die liquiden Mittel auf 310,6 MSEK (74,7).
Am 28. Juli wurde bekannt gegeben, dass Surgical Science eine Vereinbarung zur Übernahme von Simbionix getroffen hat. Am 16. August fand eine außerordentliche Hauptversammlung statt, auf der die gezielte Aktienausgabe zur Finanzierung der Übernahme genehmigt wurde. Der Eigentumsübergang fand am 24. August statt, und Simbionix wird ab diesem Datum konsolidiert.
ERSTE NEUN MONATE 2021 (JAN - SEP)
Der Nettoumsatz belief sich auf 169,1 Mio. SEK (65,2), was einer Steigerung von 159 Prozent gegenüber dem entsprechenden Vorjahreszeitraum entspricht.
Bei vergleichbaren Einheiten stieg der Umsatz um 36 Prozent.
Das Betriebsergebnis belief sich auf 12,0 MSEK (7,3). Das Ergebnis enthält Erwerbskosten in Höhe von 28,1 MSEK.
Das Nettoergebnis belief sich auf 19,4 MSEK (5,0), was einem Ergebnis je Aktie von 0,49 MSEK (0,15) entspricht.
Der Cashflow aus betrieblicher Tätigkeit belief sich auf 52,1 MSEK (6,6).
Im Januar wurde das Unternehmen Mimic Technologies Inc. erworben, das in der Roboterchirurgie tätig ist. Der Eigentumsübergang fand am 27. Januar statt.
Göteborg, Schweden, 10. November 2021
Surgical Science Sweden AB (publ)
Dieser Bericht ist in seiner Gesamtheit über den Anhang oder über verfügbar:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
Bin seit Juli 2020 investiert mit EK von 7,40€
DRITTES QUARTAL 2021 (JUL - SEP)
Der Nettoumsatz belief sich auf 95,3 Mio. SEK (24,9), was einer Steigerung von 282 Prozent gegenüber dem entsprechenden Vorjahreszeitraum entspricht. Simbionix ist in Höhe von 50,3 MSEK enthalten.
Bei vergleichbaren Einheiten stieg der Umsatz um 31 Prozent.
Das Betriebsergebnis belief sich auf 7,6 MSEK (7,3). Das Ergebnis enthält Erwerbskosten in Höhe von 21,8 MSEK.
Das Nettoergebnis belief sich auf 14,4 MSEK (5,9), was einem Ergebnis je Aktie von 0,33 MSEK (0,17) entspricht.
Der Cashflow aus betrieblicher Tätigkeit belief sich auf 51,6 MSEK (9,2). Zum 30. September 2021 beliefen sich die liquiden Mittel auf 310,6 MSEK (74,7).
Am 28. Juli wurde bekannt gegeben, dass Surgical Science eine Vereinbarung zur Übernahme von Simbionix getroffen hat. Am 16. August fand eine außerordentliche Hauptversammlung statt, auf der die gezielte Aktienausgabe zur Finanzierung der Übernahme genehmigt wurde. Der Eigentumsübergang fand am 24. August statt, und Simbionix wird ab diesem Datum konsolidiert.
ERSTE NEUN MONATE 2021 (JAN - SEP)
Der Nettoumsatz belief sich auf 169,1 Mio. SEK (65,2), was einer Steigerung von 159 Prozent gegenüber dem entsprechenden Vorjahreszeitraum entspricht.
Bei vergleichbaren Einheiten stieg der Umsatz um 36 Prozent.
Das Betriebsergebnis belief sich auf 12,0 MSEK (7,3). Das Ergebnis enthält Erwerbskosten in Höhe von 28,1 MSEK.
Das Nettoergebnis belief sich auf 19,4 MSEK (5,0), was einem Ergebnis je Aktie von 0,49 MSEK (0,15) entspricht.
Der Cashflow aus betrieblicher Tätigkeit belief sich auf 52,1 MSEK (6,6).
Im Januar wurde das Unternehmen Mimic Technologies Inc. erworben, das in der Roboterchirurgie tätig ist. Der Eigentumsübergang fand am 27. Januar statt.
Göteborg, Schweden, 10. November 2021
Surgical Science Sweden AB (publ)
Dieser Bericht ist in seiner Gesamtheit über den Anhang oder über verfügbar:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
16.02.22 13:49
#6
Tamakoschy
Q4 - Boden gefunden?
https://view.news.eu.nasdaq.com/...4c3b0981bcdc53c85b43f2&lang=en
11.05.22 16:19
#7
Tamakoschy
Q1 - gute Zahlen
https://view.news.eu.nasdaq.com/...e095d42316d2bccc361920&lang=en
nterim report January-March 2022: A STRONG START TO THE YEAR
FIRST QUARTER 2022 (JAN – MAR)
Net sales amounted to SEK 159.1 million (37.2), corresponding to an increase of 328 percent compared with the corresponding period in the preceding year.
Simbionix is included in the amount of SEK 115.2 million. For comparable units, sales increased by 32 percent.
Operating profit amounted to SEK 20.0 million (2.2).
Net profit amounted to SEK 16.5 million (1.5), corresponding to earnings per share of SEK 0.32 (0.04).
Cash flow from operating activities amounted to an inflow of SEK 11.1 million (outflow 8.9). As of March 31, 2022, cash and cash equivalents amounted to SEK 329.9 million (263.7).
Gothenburg, Sweden, May 11, 2022
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.
For further information, please contact:
Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com
Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com
About Surgical Science Sweden AB (publ)
One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the clinical environment. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.
Surgical Science has more than 200 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Stockholm, Sweden, as well as in Tel Aviv, Israel and Seattle, US. Through sales offices in the US, France and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Phone: +46 8-463 83 00; E-mail: certifiedadviser@penser.se).
This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-05-11 07:30 CEST.
Attachments:
220511 Q12022 ENG.pdf
nterim report January-March 2022: A STRONG START TO THE YEAR
FIRST QUARTER 2022 (JAN – MAR)
Net sales amounted to SEK 159.1 million (37.2), corresponding to an increase of 328 percent compared with the corresponding period in the preceding year.
Simbionix is included in the amount of SEK 115.2 million. For comparable units, sales increased by 32 percent.
Operating profit amounted to SEK 20.0 million (2.2).
Net profit amounted to SEK 16.5 million (1.5), corresponding to earnings per share of SEK 0.32 (0.04).
Cash flow from operating activities amounted to an inflow of SEK 11.1 million (outflow 8.9). As of March 31, 2022, cash and cash equivalents amounted to SEK 329.9 million (263.7).
Gothenburg, Sweden, May 11, 2022
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.
For further information, please contact:
Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com
Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com
About Surgical Science Sweden AB (publ)
One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the clinical environment. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.
Surgical Science has more than 200 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Stockholm, Sweden, as well as in Tel Aviv, Israel and Seattle, US. Through sales offices in the US, France and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Phone: +46 8-463 83 00; E-mail: certifiedadviser@penser.se).
This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-05-11 07:30 CEST.
Attachments:
220511 Q12022 ENG.pdf
10.11.22 10:33
#8
Tamakoschy
Q3
https://www.marketscreener.com/quote/stock/...K-200-MILLION-42263060/
Interim report January-September 2022: FIRST QUARTER WITH SALES ABOVE SEK 200 MILLION
11/10/2022 | 06:31am GMT
THIRD QUARTER 2022 (JUL – SEP)
Net sales amounted to SEK 205.1 million (95.3), corresponding to an increase of 115 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 39 percent.
Operating profit amounted to SEK 42.7 million (7.6).
Net profit amounted to SEK 28.5 million (14.4), corresponding to earnings per share of SEK 0.56 (0.33).
Cash flow from operating activities amounted to an inflow of SEK 9.5 million (51.6). As of September 30, 2022, cash and cash equivalents amounted to SEK 370.1 million (310.6).
FIRST NINE MONTHS OF 2022 (JAN–SEP)
Net sales amounted to SEK 552.4 million (169.1), corresponding to an increase of 227 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 39 percent.
Operating profit amounted to SEK 101.3 million (12.0).
Net profit amounted to SEK 71.5 million (19.4), corresponding to earnings per share of SEK 1.41 (0.49).
Cash flow from operating activities amounted to an inflow of SEK 50.9 million (52.1).
Gothenburg, Sweden, November 10, 2022
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.
Interim report January-September 2022: FIRST QUARTER WITH SALES ABOVE SEK 200 MILLION
11/10/2022 | 06:31am GMT
THIRD QUARTER 2022 (JUL – SEP)
Net sales amounted to SEK 205.1 million (95.3), corresponding to an increase of 115 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 39 percent.
Operating profit amounted to SEK 42.7 million (7.6).
Net profit amounted to SEK 28.5 million (14.4), corresponding to earnings per share of SEK 0.56 (0.33).
Cash flow from operating activities amounted to an inflow of SEK 9.5 million (51.6). As of September 30, 2022, cash and cash equivalents amounted to SEK 370.1 million (310.6).
FIRST NINE MONTHS OF 2022 (JAN–SEP)
Net sales amounted to SEK 552.4 million (169.1), corresponding to an increase of 227 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 39 percent.
Operating profit amounted to SEK 101.3 million (12.0).
Net profit amounted to SEK 71.5 million (19.4), corresponding to earnings per share of SEK 1.41 (0.49).
Cash flow from operating activities amounted to an inflow of SEK 50.9 million (52.1).
Gothenburg, Sweden, November 10, 2022
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.
22.02.23 17:04
#9
Tamakoschy
Q4 feine Zahlen
https://view.news.eu.nasdaq.com/...7820cd599166802ffe51ef&lang=en
Surgical Science Sweden AB
Interim information
Year-end report 2022: STRONG END TO AN AMAZING YEAR
FOURTH QUARTER 2022 (OCT – DEC)
Net sales amounted to SEK 250.1 million (197.7), corresponding to an increase of 27 percent compared with the corresponding period in the preceding year. The preceding year's figure included an item of SEK 9.5 million attributable to the adjustment of accounting principles regarding the period in which certain income is reported. Adjusted for this item, sales increased by 33 percent.
Operating profit amounted to SEK 61.2 million (44.5).
Net profit amounted to SEK 116.5 million (66.9), corresponding to earnings per share of SEK 2.29 (1.32).
Cash flow from operating activities amounted to an inflow of SEK 78.5 million (outflow 13.0). As of December 31, 2022, cash and cash equivalents amounted to SEK 433.7 million (316.7).
FULL-YEAR 2022
Net sales amounted to SEK 802.5 million (366.8), corresponding to an increase of 119 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 34 percent.
Operating profit amounted to SEK 162.5 million (56.5).
Net profit amounted to SEK 188.0 million (86.2), corresponding to earnings per share of SEK 3.70 (2.03).
Cash flow from operating activities amounted to an inflow of SEK 129.5 million (39.1).
Surgical Science Sweden AB
Interim information
Year-end report 2022: STRONG END TO AN AMAZING YEAR
FOURTH QUARTER 2022 (OCT – DEC)
Net sales amounted to SEK 250.1 million (197.7), corresponding to an increase of 27 percent compared with the corresponding period in the preceding year. The preceding year's figure included an item of SEK 9.5 million attributable to the adjustment of accounting principles regarding the period in which certain income is reported. Adjusted for this item, sales increased by 33 percent.
Operating profit amounted to SEK 61.2 million (44.5).
Net profit amounted to SEK 116.5 million (66.9), corresponding to earnings per share of SEK 2.29 (1.32).
Cash flow from operating activities amounted to an inflow of SEK 78.5 million (outflow 13.0). As of December 31, 2022, cash and cash equivalents amounted to SEK 433.7 million (316.7).
FULL-YEAR 2022
Net sales amounted to SEK 802.5 million (366.8), corresponding to an increase of 119 percent compared with the corresponding period in the preceding year.
For comparable units, sales increased by 34 percent.
Operating profit amounted to SEK 162.5 million (56.5).
Net profit amounted to SEK 188.0 million (86.2), corresponding to earnings per share of SEK 3.70 (2.03).
Cash flow from operating activities amounted to an inflow of SEK 129.5 million (39.1).
16.05.23 09:39
#10
Tamakoschy
Q1 wieder Top Zahlen
https://www.marketscreener.com/quote/stock/...VERY-STRONGLY-43860253/
Interim report January – March 2023: 2023 STARTED VERY STRONGLY
05/16/2023 | 06:32am BST
FIRST QUARTER 2023 (JAN – MAR)
Net sales amounted to SEK 229.1 million (159.1), corresponding to an increase of 44 percent compared with the corresponding period in the preceding year.
License revenues roughly doubled to SEK 70.6 million (35.7) and accounted for 31 percent of net sales (22).
Operating profit amounted to SEK 53.3 million (20.0).
Net profit amounted to SEK 49.8 million (16.5), corresponding to earnings per share of SEK 0.98 (0.32).
Cash flow from operating activities amounted to SEK 60.5 million (11.1). As of March 31, 2023, cash and cash equivalents amounted to SEK 482.1 million (329.9).
Gothenburg, Sweden, May 16, 2023
Surgical Science Sweden AB (publ)
Interim report January – March 2023: 2023 STARTED VERY STRONGLY
05/16/2023 | 06:32am BST
FIRST QUARTER 2023 (JAN – MAR)
Net sales amounted to SEK 229.1 million (159.1), corresponding to an increase of 44 percent compared with the corresponding period in the preceding year.
License revenues roughly doubled to SEK 70.6 million (35.7) and accounted for 31 percent of net sales (22).
Operating profit amounted to SEK 53.3 million (20.0).
Net profit amounted to SEK 49.8 million (16.5), corresponding to earnings per share of SEK 0.98 (0.32).
Cash flow from operating activities amounted to SEK 60.5 million (11.1). As of March 31, 2023, cash and cash equivalents amounted to SEK 482.1 million (329.9).
Gothenburg, Sweden, May 16, 2023
Surgical Science Sweden AB (publ)
24.08.23 09:36
#11
Tamakoschy
Q2
https://www.marketscreener.com/quote/stock/...TRONG-CASH-FL-44684850/
Interim report January – June 2023: LICENSE REVENUE CONTINUED TO INCREASE, VERY STRONG CASH FLOW
Today at 01:31 am
SECOND QUARTER 2023 (APR – JUN)
Net sales amounted to SEK 216.2 million (188.2), corresponding to an increase of 15 percent compared with the corresponding period in the preceding year.
License revenue amounted to SEK 75.7 million (45.4) and accounted for 35 percent of net sales (24).
Operating profit amounted to SEK 47.5 million (38.6).
Net profit amounted to SEK 38.8 million (26.5), corresponding to earnings per share of SEK 0.76 (0.52).
Cash flow from operating activities amounted to SEK 85.1 million (30.4). As of June 30, 2023, cash and cash equivalents amounted to SEK 574.4 million (362.3).
FIRST HALF OF 2023 (JAN – JUN)
Net sales amounted to SEK 445.3 million (347.4), corresponding to an increase of 28 percent compared with the corresponding period in the preceding year.
Operating profit amounted to SEK 100.8 million (58.6).
Net profit amounted to SEK 88.6 million (43.0), corresponding to earnings per share of SEK 1.74 (0.85).
Cash flow from operating activities amounted to SEK 145.6 million (41.5).
Gothenburg, Sweden, August 24, 2023
Surgical Science Sweden AB (publ)
Interim report January – June 2023: LICENSE REVENUE CONTINUED TO INCREASE, VERY STRONG CASH FLOW
Today at 01:31 am
SECOND QUARTER 2023 (APR – JUN)
Net sales amounted to SEK 216.2 million (188.2), corresponding to an increase of 15 percent compared with the corresponding period in the preceding year.
License revenue amounted to SEK 75.7 million (45.4) and accounted for 35 percent of net sales (24).
Operating profit amounted to SEK 47.5 million (38.6).
Net profit amounted to SEK 38.8 million (26.5), corresponding to earnings per share of SEK 0.76 (0.52).
Cash flow from operating activities amounted to SEK 85.1 million (30.4). As of June 30, 2023, cash and cash equivalents amounted to SEK 574.4 million (362.3).
FIRST HALF OF 2023 (JAN – JUN)
Net sales amounted to SEK 445.3 million (347.4), corresponding to an increase of 28 percent compared with the corresponding period in the preceding year.
Operating profit amounted to SEK 100.8 million (58.6).
Net profit amounted to SEK 88.6 million (43.0), corresponding to earnings per share of SEK 1.74 (0.85).
Cash flow from operating activities amounted to SEK 145.6 million (41.5).
Gothenburg, Sweden, August 24, 2023
Surgical Science Sweden AB (publ)
24.08.23 15:07
#12
Tamakoschy
Bericht ausführlicher
https://storage.mfn.se/...bab-aa8b-f80ecc6154b5/230824-q22023-eng.pdf
30.11.23 09:29
#13
tinelli
im Aktienfinder
YouTube Video
https://www.youtube.com/watch?v=Dqy2H5j1rRU
https://www.youtube.com/watch?v=Dqy2H5j1rRU